O,N-dibenzyl hydroxylamine hydrochloride | 5555-54-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O,N-dibenzyl hydroxylamine hydrochloride
• 英文别名: N-benzyl-O-benzylhydroxylamine hydrochloride；1-phenyl-N-phenylmethoxymethanamine;hydrochloride
• CAS: 5555-54-4
• 化学式: C₁₄H₁₅NO*ClH
• 分子量: 249.74
• InChiKey: UZUZFQGQSFJGER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.33
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  O,N-dibenzyl hydroxylamine hydrochloride 在 双(三甲基硅烷基)氨基钾 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 4.33h， 生成 (S)-2-Benzyl-4-oxo-azetidine-1-carboxylic acid benzyl-benzyloxy-amide
  参考文献：
  名称：

  β-Lactam Derivatives as Inhibitors of Human Cytomegalovirus Protease

  摘要：

  The development of novel monobactam inhibitors of HCMV protease incorporating a carbon side chain at C-4 and a urea function at N-1 is described. Substitution with small groups at the C-3 position of the beta-lactam ring gave an increase in enzymatic activity and in stability; however, a lack of selectivity against other serine proteases was noted. The use of both tri- and tetrasubstituted urea functionalities gave effective inhibitors of HCMV protease. Benzyl substitution of the urea moiety was beneficial, especially when strong electron-withdrawing groups where attached at the para position. Modest antiviral activity was found in a plaque reduction assay.

  DOI：

  10.1021/jm980131z
• 作为产物：
  描述：

  N-(diethoxyphosphoryl)-O-benzylhydroxylamine 在 盐酸 、 四丁基溴化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.08h， 生成 O,N-dibenzyl hydroxylamine hydrochloride
  参考文献：
  名称：

  N-（二乙氧基磷酰基）-O-苄基羟胺-方便的底物，用于合成N-取代的O-苄基羟胺

  摘要：

  已表明，在碱性条件下（氢化钠/四丁基溴化铵），通过各种卤化物，易于获得的N-（二乙氧基磷酰基）-O-苄基羟胺是一种方便的，受正交保护的底物，用于区域选择性N-烷基化。还建立了用于N-取代的N-（二乙氧基磷酰基）-O-苄基羟胺的去磷酸化以提供N-取代的O-苄基羟胺的有效方法。

  DOI：

  10.1016/j.tet.2003.10.056

文献信息

• Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102600A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及一种具有通式I的化合物，可选地以药物可接受的盐、溶剂化物、多晶型、前药、互变异构体、外消旋体、对映体、非对映体或其混合物的形式，该化合物在治疗、改善或预防病毒性疾病方面有用。此外，还公开了特定的组合疗法。
• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• Azolobenzazepine derivatives as neurologically active agents
  申请人：Zeneca Limited

  公开号：US06124281A1

  公开（公告）日：2000-09-26

  The invention relates to azolobenzazepine derivatives of formula (I), wherein: X is O or S; R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently hydrogen, perfluorolower-alkyl, halogen, nitro or cyano; and C together with the carbon atoms to which it is attached forms a 5-membered aromatic heterocycle selected from the group consisting of a pyrazol and triazole, to pharmaceutical compositions containing them and to methods for the treatment of neurological disorders utilizing them. ##STR1##

  这项发明涉及式(I)的氮杂苯并蒽啉衍生物，其中：X为O或S；R.sup.1、R.sup.2、R.sup.3和R.sup.4分别为氢、全氟较低烷基、卤素、硝基或氰基；C与其连接的碳原子一起形成从吡唑和三唑组成的5-成员芳香杂环，以及含有它们的药物组合物和利用它们治疗神经系统疾病的方法。
• Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102601A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有通式II的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、前药、互变异构体、消旋体、对映体或二对映体或其混合物的形式存在，用于治疗、改善或预防病毒性疾病。此外，还披露了特定的联合疗法。
• Nitrosation of dialkylhydroxylamines, and computational and NMR investigations of the interconversion of conformational isomers of <i>N</i> -nitroso-dimethylhydroxylamine
  作者：Juan Crugeiras、Howard Maskill、William MacFarlane、Iain D. Menneer、Ana Rios、Miguel A. Rios

  DOI：10.1002/poc.1723

  日期：2011.2

  9 × 109 dm3 mol−1 s−1). In contrast, there is only a very slight increase in kobs with increasing [H3O+] for nitrosation of N,O‐dimethylhydroxylamine (4) in dilute aqueous solution at 25 °C to give N‐nitroso‐dimethylhydroxylamine, 5. This also fits a two‐channel mechanism (Scheme 3). Again, one involves the nitrosation of the free base by NO+ (k2 = 8 × 109 dm3 mol−1 s−1, 25 °C) but the other channel now involves

  研究了酸度对25°C下1：1（v / v）H 2 O / MeOH中N-苄基，O-甲基羟胺（3）亚硝化速率的影响。随着[H 3 O + ]的增加，随着限制试剂的减少，HNO 2损失的拟一级反应速率常数（k obs）。这与两个平行的反应通道兼容（方案2）。一种涉及游离羟胺与HNO 2（k 1  = 1.4×10 2  dm 3  mol-1  s -1，25 ℃），另一个涉及游离羟胺与NO +的反应（k 2  = 5.9×10 9  dm 3  mol -1  s -1）。相比之下，在25°C的稀水溶液中，N，O-二甲基羟胺（4）的亚硝化作用[H 3 O + ]增加时，k obs仅有很小的增加，从而得到N-亚硝基二甲基羟胺5。这也符合两通道机制（方案3）。同样，一个通道涉及NO +对游离碱的亚硝化（k 2  = 8×10 9  dm 3  mol -1  s -1，25 °C），但另一个通道现在涉及氯化物的催化作用（k